Natural history, outcome, and sustainability of treatment response in chronic viral hepatitis B: Thai multicenter study

1. Pramoolsinsap C, Pukrittayakamee S, Desakorn V. Hepatitis B problem in Thailand. Southeast Asian J Trop Med Public Health. 1986; 17:219-28.Search in Google Scholar

2. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000; 15:1356-61.10.1046/j.1440-1746.2000.0150121356.x11197043Open DOISearch in Google Scholar

3. Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapeliere P, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J. 1992; 11:816-21.10.1097/00006454-199210000-000021408478Open DOISearch in Google Scholar

4. Poovorawan Y, Chatchatee P, Chongsrisawat V. Epidemiology and prophylaxis of viral hepatitis: a global perspective. J Gastroenterol Hepatol. 2002; 17 (Suppl): S155-66.10.1046/j.1440-1746.17.s1.4.x12000601Open DOISearch in Google Scholar

5. Lau GK, Carman WF, Locarnini SA, Okuda K, Lu ZM, Williams R, et al. Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. J Gastroenterol Hepatol. 1999; 14:3-12.10.1046/j.1440-1746.1999.01812.x10029271Open DOISearch in Google Scholar

6. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000; 15 (Suppl):E25-30.10.1046/j.1440-1746.2000.02097.x10921378Open DOISearch in Google Scholar

7. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004; 53:744-9.10.1136/gut.2003.020263177405515082595Open DOISearch in Google Scholar

8. Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000; 15 Suppl:E20-4.10.1046/j.1440-1746.2000.02123.x10921377Open DOISearch in Google Scholar

9. Zacharakis GH, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/ECproject). J Med Virol. 2005; 77:173-9.10.1002/jmv.2043416121378Open DOISearch in Google Scholar

10. Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2000; 15 (Suppl):E53-60.10.1046/j.1440-1746.2000.02103.x10921383Open DOISearch in Google Scholar

11. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002; 9: 393-9.10.1046/j.1365-2893.2002.00388.x12431200Open DOISearch in Google Scholar

12. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119: 172-80.10.1053/gast.2000.8559Open DOISearch in Google Scholar

13. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol. 2006; 4:666-76.10.1016/j.cgh.2006.03.017Open DOISearch in Google Scholar

14. Yuen MF, Lai CL. Recommendations and potential future options in the treatment of hepatitis B. Expert Opin Pharmacother. 2006; 7:2225-31.10.1517/14656566.7.16.2225Search in Google Scholar

15. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26:130-41.10.1055/s-2006-939751Open DOISearch in Google Scholar

16. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1:431-5.10.1002/hep.1840010511Open DOISearch in Google Scholar

17. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45:1056-75.10.1002/hep.21627Open DOISearch in Google Scholar

18. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46:254-65.10.1002/hep.21698Open DOISearch in Google Scholar

19. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 25 (Suppl 1):3-8.10.1055/s-2005-915644Open DOISearch in Google Scholar

20. Ganem D, Prince AM. Hepatitis B virus infection- natural history and clinical consequences. N Engl J Med. 2004; 350:1118-29.10.1056/NEJMra031087Open DOISearch in Google Scholar

21. Ribeiro RM, Lo A, Perelson AS. Dynamics of hepatitis B virus infection. Microbes Infect. 2002; 4:829-35.10.1016/S1286-4579(02)01603-9Open DOISearch in Google Scholar

22. Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008; 48:335-52.10.1016/j.jhep.2007.11.011Open DOISearch in Google Scholar

23. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95.10.1056/NEJMoa043470Open DOISearch in Google Scholar

24. Cooksley G. The treatment of hepatitis B e antigenpositive chronic hepatitis B with pegylated interferon. J Hepatol. 2003; 39 (Suppl 1):S143-5.10.1016/S0168-8278(03)00327-1Open DOISearch in Google Scholar

25. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365 (9454):123-9.10.1016/S0140-6736(05)17701-0Search in Google Scholar

26. Bedossa P B-SP, Callard P, Chevallier M, Degott C, Deugnier Y, et al. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994; 20:15-20.10.1002/hep.1840200104Open DOISearch in Google Scholar

27. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996; 25:649-54.10.1016/S0168-8278(96)80234-0Open DOISearch in Google Scholar

28. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut. 2007; 56:699-705.10.1136/gut.2005.089722194215217127704Open DOISearch in Google Scholar

29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008; 47:428-34.10.1002/hep.2206518220290Open DOISearch in Google Scholar

30. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142:240-50.10.7326/0003-4819-142-4-200502150-0000615710957Open DOISearch in Google Scholar

31. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001; 33:1527-32.10.1053/jhep.2001.2508411391543Search in Google Scholar

32. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004; 19:1276-82.10.1111/j.1440-1746.2004.03428.x15482535Open DOISearch in Google Scholar

33. Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004; 19:323-9.10.1111/j.1365-2036.2004.01845.x14984379Open DOISearch in Google Scholar

34. Hui CK, Lau GK. Treatment of hepatitis B e antigennegative patients. Curr Treat Options Gastroenterol. 2007; 10:474-82.10.1007/s11938-007-0047-618221608Search in Google Scholar

35. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005; 42:121-9.10.1002/hep.2076015962291Open DOISearch in Google Scholar

36. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004; 40:883-91.10.1002/hep.1840400418Open DOISearch in Google Scholar

37. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351:1206-17.10.1056/NEJMoa04043115371578Open DOISearch in Google Scholar

38. Zhang DZ. [Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2007; 15:876-7.Search in Google Scholar

39. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban- Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007; 5:890-7.10.1016/j.cgh.2007.05.00417632041Open DOISearch in Google Scholar

40. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat. 2007; 14:751-66.10.1111/j.1365-2893.2007.00865.x215615117927611Open DOISearch in Google Scholar

41. Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res. 2007; 37 (s1):S67-78.10.1111/j.1872-034X.2007.00108.x17627639Open DOISearch in Google Scholar

42. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008; 15:137-45.10.1007/s11373-007-9225-818058038Open DOISearch in Google Scholar

43. Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol. 2007; 5:1454-61.10.1016/j.cgh.2007.08.008264578817977800Open DOISearch in Google Scholar

44. Perrillo RP, Jacobson IM. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis. 2007; 27 (Suppl 1):3-8. 10.1055/s-2007-98469417701844Open DOISearch in Google Scholar